BSX Raises 2025 Financial Outlook: What's Backing It?

Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum across key growth areas. The company now anticipates net sales to grow approximately 15-17% on a reported basis (earlier 12.5-14.5%) and nearly 12-14% on an organic basis (earlier 10-12%). Full-year adjusted earnings per share are expected to be in the range of $2.87-$2.94 (previously $2.80-$2.87). On the flip side, the company expects a $200 million tariff impact in 2025, mainly in the second half.

In the first quarter, the company delivered organic sales growth of 18%, exceeding the guided range of 14-16%. Adjusted EPS was $0.75, marking a 34% year-over-year increase and surpassing the forecasted $0.66-$0.68 range. This growth reflects the durability of BSX’s category leadership strategy, which is powered through meaningful innovation and clinical evidence generation. 

Boston Scientific’s Cardiology segment sales surged 31%, driven by robust growth in products such as WATCHMAN, AGENT drug-coated balloon (DCB) and FARAPULSE. WATCHMAN gained market share through rising concomitant procedures. In addition, its Electrophysiology (“EP”) business experienced robust growth, with sales up 145% year over year. This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation (PFA) with FARAPULSE. Geographically, sales in the United States rose 31%, while Asia-Pacific and EMEA regions delivered 11% and 8% sales growth, respectively. Asia-Pacific growth was led by double-digit growth in Japan and high single-digit growth in China (despite volume-based procurement headwinds).

BSX also plans to successfully offset the tariff impact through full-year organic sales guidance raise, targeted discretionary spending reductions and a $0.01FX benefit.

Boston Scientific’s Competitors

Edwards Lifesciences EW reiterated its 2025 sales growth forecast of 8-10% but raised the sales dollar guidance range by $100 million, reaching $5.7-$6.1 billion.  The revision was made to account for the recent movement in foreign exchange rates. Edwards continues to expect 2025 adjusted EPS to be in the range of $2.40-$2.50 despite headwinds from tariffs. This growth trajectory is driven by the continued global adoption of SAPIEN 3 Ultra RESILIA, PASCAL and EVOQUE systems. 

Stryker SYK raised its sales guidance for 2025, led by strong first-quarter performance, continued capital demand and robust commercial execution. The company now expects total revenues to grow in the range of 8.5-9.5% on an organic basis (previously 8-9%). However, SYK lowered its EPS guidance to $13.20-$13.45 from $13.45-$13.70, reflecting headwinds from the Inari Medical acquisition and a $200 million impact from announced tariffs. 

BSX Stock Price Performance, Valuation and Estimate Trend

Shares of Boston Scientific have gained 33.4% in the past year compared with the industry’s growth of 8.8%. The S&P 500 composite has grown 9.3% in the same period.

Image Source: Zacks Investment Research

From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 33.19X, above the industry’s 20.83X. 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.

Image Source: Zacks Investment Research

BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Names #1 Semiconductor Stock

It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com